Exactech Q3 Revenue Up 4% to $57.9 Million; Net Income Down 6% to $3.0 Million Due to Currency Losses; Q3 Diluted EPS $0.21 vs. $0.23

Exactech Schedules Q3 2014 Earnings Release and Conference Call

Exactech Innovations Presented at Recent Key Scientific Conferences

Exactech Announces First Implantation of New Alteon™ Tapered Wedge Femoral Stem

Exactech Q2 Revenue Up 6% to $63.9 Million. Net Income up 12% to $4.2 Million. Diluted EPS $0.30 vs. $0.27

Exactech Schedules Second Quarter 2014 Earnings Release and Conference Call

Exactech Launches New Porous Technology for Total Knee Arthroplasty

Twenty ExactechGPS® Guided Personalized Surgery Abstracts Accepted into Five Leading Orthopaedic Conferences

Exactech Announces First International Introduction of ExactechGPS® Guided Personalized Surgery at 15th EFORT Congress

W. Andrew Krusen Elected to Exactech Board of Directors